An update on cardiomyopathies: immune-mediated diseases, sarcoidosis, and peripartum and hypertrophic cardiomyopathies during pregnancy Eur. Heart J. (IF 19.651) Pub Date : 2017-09-14 Thomas F. Lüscher
Spencer B. King III MD FACC Eur. Heart J. (IF 19.651) Pub Date : 2017-09-14 Judy Ozkan
Spencer King is still at Emory University, Atlanta, Georgia, USA, where he was instrumental in enabling Andreas Roland Grüntzig to succeed
Arrhythmias at the Munich Octoberfest: ECG under the influence? Eur. Heart J. (IF 19.651) Pub Date : 2017-09-14 Moritz F. Sinner, Stefan Brunner
The Munich Octoberfest is a well-known traditional public festival celebrated annually in Munich, Germany. The 184th anniversary—from 16 September to 3 October 2017—is rapidly approaching. During its 16 days duration, it will again attract 6–7 million visitors from near and far who will consume over 7 million litres of beer.1 Whereas most visitors drink responsibly, some exaggerate by binge drinking: out of 6478 patient contacts with the on-site emergency medical service in 2015, 609 were for excessive alcohol consumption requiring medical attention.2
ESC Apps for Atrial Fibrillation Eur. Heart J. (IF 19.651) Pub Date : 2017-09-14 Dipak Kotecha, Paulus Kirchhof
Novel Smartphone and Tablet Apps for patients and healthcare professionals have been developed by the European Society of Cardiology based on the 2016 ESC Guidelines for Atrial Fibrillation
Other Metrics: beyond the Impact Factor Eur. Heart J. (IF 19.651) Pub Date : 2017-09-14 David Crotty
In the previous article of this series, in the immediately preceding CardioPulse, we looked at the Impact Factor (IF), noted its flaws, and discussed where it is valuable. The key message was that rather than a reductionist approach of trying to find one single perfect metric, we are better served by looking at a variety of measures geared toward the question being asked.
Altmetrics Eur. Heart J. (IF 19.651) Pub Date : 2017-09-14 David Crotty
David Crotty PhD concludes his series of four articles discussing the difficult area of different metrics for journals and researchers
Diagnosis and management of myocardial involvement in systemic immune-mediated diseases: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Disease Eur. Heart J. (IF 19.651) Pub Date : 2017-06-26 Alida L.P. Caforio, Yehuda Adler, Carlo Agostini, Yannick Allanore, Aris Anastasakis, Michael Arad, Michael Böhm, Philippe Charron, Perry M. Elliott, Urs Eriksson, Stephan B. Felix, Pablo Garcia-Pavia, Eric Hachulla, Stephane Heymans, Massimo Imazio, Karin Klingel, Renzo Marcolongo, Marco Matucci Cerinic, Antonis Pantazis, Sven Plein, Valeria Poli, Angelos Rigopoulos, Petar Seferovic, Yehuda Shoenfeld, Josè L Zamorano, Ales Linhart
Systemic immune-mediated diseases (SIDs) include autoimmune and autoinflammatory diseases (AD) affecting at least two-organ systems.1 Autoinflammatory diseases refer to a growing family of conditions characterised by episodes of unprovoked inflammation in the absence of high autoantibody titres or auto reactive T lymphocytes, reflecting a primary innate immune system dysfunction.1 Conversely, autoimmune diseases are characterised by aberrant B, T and dendritic cell responses, leading to a break in tolerance against self-antigens, with predominantly cell-mediated or autoantibody-mediated responses in genetically susceptible individuals.2–11 Autoantibodies (AAbs), when detectable, can promote inflammatory responses via immune complex formation and may directly affect target organ function,10 e.g. resulting, in cardiac autoimmunity, in electrical disturbance, cardiomyocyte dysfunction or loss and heart failure.12–15 However, a dichotomous classification does not reflect clinical evidence and...
Cardiac manifestations of sarcoidosis: diagnosis and management Eur. Heart J. (IF 19.651) Pub Date : 2016-07-28 David H. Birnie, Riina Kandolin, Pablo B. Nery, Markku Kupari
Approximately 5% of patients with sarcoidosis will have clinically manifest cardiac involvement presenting with one or more of ventricular arrhythmias, conduction abnormalities, and heart failure. Cardiac presentations can be the first (and/or an unrecognized) manifestation of sarcoidosis in a variety of circumstances. Cardiac symptoms are usually dominant over extra-cardiac as most patients with clinically manifest disease have minimal extra-cardiac disease and up to two-thirds have isolated cardiac sarcoidosis (CS). It is estimated that another 20–25% of pulmonary/systemic sarcoidosis patients have asymptomatic cardiac involvement (clinically silent disease). The extent of left ventricular dysfunction seems to be the most important predictor of prognosis among patients with clinically manifest CS. In addition, the extent of myocardial late gadolinium enhancement is emerging as an important prognostic factor. The literature shows some controversy regarding outcomes for patients with clinically silent CS and larger studies are needed. Immunosuppression therapy (usually with corticosteroids) has been suggested for the treatment of clinically manifest CS despite minimal data supporting it. Fluorodeoxyglucose Positron Emission Tomography imaging is often used to detect active disease and guide immunosuppression. Patients with clinically manifest disease often need device therapy, typically with implantable cardioverter defibrillators.
Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study Eur. Heart J. (IF 19.651) Pub Date : 2017-07-27 Denise Hilfiker-Kleiner, Arash Haghikia, Dominik Berliner, Jens Vogel-Claussen, Johannes Schwab, Annegret Franke, Marziel Schwarzkopf, Philipp Ehlermann, Roman Pfister, Guido Michels, Ralf Westenfeld, Verena Stangl, Ingrid Kindermann, Uwe Kühl, Christiane E. Angermann, Axel Schlitt, Dieter Fischer, Edith Podewski, Michael Böhm, Karen Sliwa, Johann Bauersachs
An anti-angiogenic cleaved prolactin fragment is considered causal for peripartum cardiomyopathy (PPCM). Experimental and first clinical observations suggested beneficial effects of the prolactin release inhibitor bromocriptine in PPCM.
Bromocriptine for the treatment of peripartum cardiomyopathy: welcome on BOARD Eur. Heart J. (IF 19.651) Pub Date : 2017-07-26 Mattia Arrigo, Alice Blet, Alexandre Mebazaa
This editorial refers to ‘Bromocriptine for the treatment of peripartum cardiomyopathy: a multicentre randomized study’†, by D. Hilfiker-Kleiner et al., on page 2671.
Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC) Eur. Heart J. (IF 19.651) Pub Date : 2017-05-10 S. Goland, I.M. van Hagen, G. Elbaz-Greener, U. Elkayam, A. Shotan, W.M. Merz, S.C. Enar, I.R. Gaisin, P.G. Pieper, M.R. Johnson, R. Hall, A. Blatt, J.W. Roos-Hesselink
We report the maternal and foetal outcomes at birth and after 6 months in a cohort of pregnant women with hypertrophic cardiomyopathy (HCM). Although most women with HCM tolerate pregnancy well, there is an increased risk of obstetric and cardiovascular complications.
Pregnancy in hypertrophic cardiomyopathy Eur. Heart J. (IF 19.651) Pub Date : 2017-06-21 Anjali Tiku Owens
This editorial refers to ‘Pregnancy in women with hypertrophic cardiomyopathy: data from the European Society of Cardiology initiated Registry of Pregnancy and Cardiac disease (ROPAC)’†, by S. Goland et al., on page 2683.
‘Pericarditis intestinalis’: a rare complication of esophageal resection Eur. Heart J. (IF 19.651) Pub Date : 2016-09-12 Michiel M. Winter, Mark I. van Berge Henegouwen, Jeroen C. Vis
A 57-year-old patient presented 6 months after a thoracolaparoscopic Ivor Lewis esophageal resection for T3N1M0 esophageal adenocarcinoma after neoadjuvante chemoradiotherapy, at our surgical unit with acute abdominal pain and vomiting. An intestinal obstruction was suspected.
Myocardial crystallization arising from a mitral annulus calcification Eur. Heart J. (IF 19.651) Pub Date : 2016-12-07 Alberto Cecconi, Ana Bustos García de Castro, José Juan Gómez de Diego
Mitral annulus calcification is a common degenerative disorder in the elderly, being more prevalent in patients with renal failure and in women. Caseous calcification is a rare variant characterized by a putty-like material surrounded by a calcified envelope. This disease is considerated a benign lesion; however, due to its active chronic inflammatory process, calcification can expand to adjacent structures.
Cactus aorta Eur. Heart J. (IF 19.651) Pub Date : 2017-09-12 Amira Mahrouf, Gilles Soulat, David Lebeaux, Laurence Iserin, Clement Karsenty
A 25-year-old woman with previous history of supravalvular aortic stenosis presented with febrile heart failure.
Safety of non-steroidal anti-inflammatory drugs Eur. Heart J. (IF 19.651) Pub Date : 2017-09-12 William S. Weintraub
This editorial refers to ‘Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis’, by F. Ruschitzka et al., doi: 10.1093/eurheartj/ehx508.
Corrigendum Eur. Heart J. (IF 19.651) Pub Date : 2017-09-12
Corrigendum to: ‘Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study’. Eur Heart J (2017) doi:10.1093/eurheartj/ehx512.
Women with hypertrophic cardiomyopathy have worse survival Eur. Heart J. (IF 19.651) Pub Date : 2017-09-08 Jeffrey B. Geske, Kevin C. Ong, Konstantinos C. Siontis, Virginia B. Hebl, Michael J. Ackerman, David O. Hodge, Virginia M. Miller, Rick A. Nishimura, Jae K. Oh, Hartzell V. Schaff, Bernard J. Gersh, Steve R. Ommen
Sex differences in hypertrophic cardiomyopathy (HCM) remain unclear. We sought to characterize sex differences in a large HCM referral centre population.
The management of antiplatelet therapy in acute coronary syndrome patients with thrombocytopenia: a clinical conundrum Eur. Heart J. (IF 19.651) Pub Date : 2017-09-08 Cian P. McCarthy, Gabriel Steg, Deepak L. Bhatt
Dual antiplatelet therapy (DAPT) consisting of aspirin and a P2Y12 receptor antagonist is a fundamental component of acute coronary syndrome (ACS) management, with longstanding endorsements by both the American College of Cardiology Foundation (ACCF)/American Heart Association (AHA) and the European Society of Cardiology (ESC).1,2 Dual antiplatelet therapy reduces the risk of both stent thrombosis and spontaneous ischaemic events, at the cost of an increased bleeding risk.3,4 The management of antiplatelet therapy in ACS patients with thrombocytopenia poses a particular challenge for physicians, as they are at higher risk of both bleeding and, paradoxically, ischaemic events.5 Unfortunately, there are currently no guideline recommendations or consensus reports to guide clinicians on the management of this cohort. In this setting, we examine the evidence to date and provide our opinion on future directions and management strategies for this group (Figure 1).
Fructose metabolism, cardiometabolic risk, and the epidemic of coronary artery disease Eur. Heart J. (IF 19.651) Pub Date : 2017-09-07 Peter Mirtschink, Cholsoon Jang, Zoltan Arany, Wilhelm Krek
Despite strong indications that increased consumption of added sugars correlates with greater risks of developing cardiometabolic syndrome (CMS) and cardiovascular disease (CVD), independent of the caloric intake, the worldwide sugar consumption remains high. In considering the negative health impact of overconsumption of dietary sugars, increased attention is recently being given to the role of the fructose component of high-sugar foods in driving CMS. The primary organs capable of metabolizing fructose include liver, small intestine, and kidneys. In these organs, fructose metabolism is initiated by ketohexokinase (KHK) isoform C of the central fructose-metabolizing enzyme KHK. Emerging data suggest that this tissue restriction of fructose metabolism can be rescinded in oxygen-deprived environments. In this review, we highlight recent progress in understanding how fructose metabolism contributes to the development of major systemic pathologies that cooperatively promote CMS and CVD, reference recent insights into microenvironmental control of fructose metabolism under stress conditions and discuss how this understanding is shaping preventive actions and therapeutic approaches.
Multivessel PCI on its 40th anniversary: finally a match for CABG? Eur. Heart J. (IF 19.651) Pub Date : 2017-09-06 Gregg W. Stone
This editorial refers to ‘Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three-vessel disease: 1-year results of the SYNTAX II study’, by J. Escaned et al., doi: 10.1093/eurheartj/ehx512.
Coronary obstruction: a rare but devastating complication during transcatheter aortic valve-in-valve implantation Eur. Heart J. (IF 19.651) Pub Date : 2017-09-06 Bernard Iung, Alec Vahanian
This editorial refers to ‘Incidence, predictors, and clinical outcomes of coronary obstruction following transcatheter aortic valve replacement for degenerative bioprosthetic surgical valves: insights from the VIVID registry’, by H.B. Ribeiro et al., doi: 10.1093/eurheartj/ehx455.
New insights into mitral valve dystrophy: a Filamin-A genotype–phenotype and outcome study Eur. Heart J. (IF 19.651) Pub Date : 2017-09-06 Thierry Le Tourneau, Solena Le Scouarnec, Caroline Cueff, Daniel Bernstein, Jan J.J. Aalberts, Simon Lecointe, Jean Mérot, Jonathan A. Bernstein, Toon Oomen, Christian Dina, Matilde Karakachoff, Hubert Desal, Ousama Al Habash, Francesca N. Delling, Romain Capoulade, Albert J.H. Suurmeijer, David Milan, Russell A. Norris, Roger Markwald, Elena Aikawa, Susan A. Slaugenhaupt, Xavier Jeunemaitre, Albert Hagège, Jean-Christian Roussel, Jean-Noël Trochu, Robert A. Levine, Florence Kyndt, Vincent Probst, Hervé Le Marec, Jean-Jacques Schott
Filamin-A (FLNA) was identified as the first gene of non-syndromic mitral valve dystrophy (FLNA-MVD). We aimed to assess the phenotype of FLNA-MVD and its impact on prognosis.
Dangerous relationships: aortic stenosis and transthyretin cardiac amyloidosis Eur. Heart J. (IF 19.651) Pub Date : 2017-09-05 Paola Gargiulo, Pasquale Perrone-Filardi
This editorial refers to ‘Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement’, by A. Castaño et al., doi: 10.1093/eurheartj/ehx350.
The Reducer device in patients with angina pectoris: mechanisms, indications, and perspectives Eur. Heart J. (IF 19.651) Pub Date : 2017-08-31 Maayan Konigstein, Francesco Giannini, Shmuel Banai
Despite available pharmacological and interventional therapies, refractory angina is a common and disabling clinical condition, and a major public health problem, which affects patients’ quality-of-life, and has a significant impact upon health care resources. Persistent angina is common not only in patients who are not good candidates for revascularization, but also in patients following successful revascularization. Clearly, there is a need for additional treatment options for refractory angina beyond currently available pharmacological and interventional therapies. It is of pivotal importance, in this condition, to practice a patient-centred health assessment approach, measuring success of a new therapy by its effects on patients’ symptoms, functional status, and quality-of-life, rather than hard clinical endpoints as used in clinical studies. The coronary sinus Reducer is a novel technology designed to reduce disabling symptoms and improve quality-of-life of patients suffering from refractory angina. This review serves to update the clinician as to current evidence and future perspectives of the optimal utilization of this innovative technology.
The definition of the Brugada syndrome Eur. Heart J. (IF 19.651) Pub Date : 2017-08-31 Juan Sieira, Pedro Brugada
Brugada syndrome (BS) is an inherited disease characterized by a coved-type ST-segment elevation in the right precordial leads and increased risk of sudden cardiac death (SCD), in the absence of structural abnormalities. The cornerstone of BS diagnosis and definition, is its characteristic ECG pattern that can be present spontaneously or unmasked by drugs. Brugada syndrome was first described 25 years ago; paradoxically, in an era of great technological development, a new syndrome was described with a technology developed almost a century before. Great scientific knowledge has been gathered since the description of the syndrome. The better understanding of its pathophysiology and genetic basis has led to several modifications in its definition. Despite these facts, the essential, the description of the specific ECG pattern has remained almost unchanged since the initial report. In this article, we present the definition of the BS, the rationale behind it and our thoughts about its future.
Looking at the Force beyond the Dark side of mechanical massage Eur. Heart J. (IF 19.651) Pub Date : 2017-08-30 Lionel Lamhaut, Alice Hutin
This editorial refers to ‘Safety of mechanical chest compression devices AutoPulse and LUCAS in cardiac arrest: a randomized clinical trial for non-inferiority’, by RW. Koster et al., doi: 10.1093/eurheartj/ehx318.
Empagliflozin across the stages of diabetic heart disease Eur. Heart J. (IF 19.651) Pub Date : 2017-08-30 Francesco Paneni
This editorial refers to ‘Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial’, by D. Fitchett et al., doi: 10.1093/eurheartj/ehx511.
Identifying patients with acute total coronary occlusion in NSTEACS: finding the high-risk needle in the haystack Eur. Heart J. (IF 19.651) Pub Date : 2017-08-30 Ranil de Silva, Philippe Gabriel Steg
This editorial refers to ‘Impact of total occlusion of culprit artery in acute non-ST elevation myocardial infarction: a systematic review and meta-analysis’, by A.R. Khan et al., doi: 10.1093/eurheartj/ehx418.
A common missense variant of LILRB5 is associated with statin intolerance and myalgia Eur. Heart J. (IF 19.651) Pub Date : 2017-08-29 Moneeza K. Siddiqui, Cyrielle Maroteau, Abirami Veluchamy, Aleksi Tornio, Roger Tavendale, Fiona Carr, Ngu-Uma Abelega, Dan Carr, Katyrzyna Bloch, Par Hallberg, Qun-Ying Yue, Ewan R. Pearson, Helen M. Colhoun, Andrew D. Morris, Eleanor Dow, Jacob George, Munir Pirmohamed, Paul M. Ridker, Alex S.F. Doney, Ana Alfirevic, Mia Wadelius, Anke-Hilse Maitland-van der Zee, Daniel I. Chasman, Colin N.A. Palmer
A genetic variant in LILRB5 (leukocyte immunoglobulin-like receptor subfamily-B) (rs12975366: T > C: Asp247Gly) has been reported to be associated with lower creatine phosphokinase (CK) and lactate dehydrogenase (LDH) levels. Both biomarkers are released from injured muscle tissue, making this variant a potential candidate for susceptibility to muscle-related symptoms. We examined the association of this variant with statin intolerance ascertained from electronic medical records in the GoDARTS study.
Homozygous familial hypercholesterolaemia: light at the end of the tunnel Eur. Heart J. (IF 19.651) Pub Date : 2017-08-29 Robert M. Stoekenbroek, G. Kees Hovingh, John J.P. Kastelein
This editorial refers to ‘Survival in homozygous familial hypercholesterolaemia is determined by the on-treatment level of serum cholesterol’, by G.R. Thompson et al., doi: 10.1093/eurheartj/ehx317.
Walking pace and handgrip strength: simple measures of fitness and mortality risk? Eur. Heart J. (IF 19.651) Pub Date : 2017-08-29 Anders Grøntved, Frank B. Hu
This editorial refers to ‘Association of walking pace and handgrip strength with all-cause, cardiovascular, and cancer mortality: a UK Biobank observational study’, by T. Yates et al., doi: 10.1093/eurheartj/ehx449.
Making sense of a seemingly odd connection Eur. Heart J. (IF 19.651) Pub Date : 2017-08-29 Alan M. Fogelman, Srinivasa T. Reddy
This editorial refers to ‘TRAK2, a novel regulator of ABCA1 expression, cholesterol efflux and HDL biogenesis’, by N.J. Lake et al., doi: 10.1093/eurheartj/ehx315.
Big data from electronic health records for early and late translational cardiovascular research: challenges and potential Eur. Heart J. (IF 19.651) Pub Date : 2017-08-29 Harry Hemingway, Folkert W. Asselbergs, John Danesh, Richard Dobson, Nikolaos Maniadakis, Aldo Maggioni, Ghislaine J.M. van Thiel, Maureen Cronin, Gunnar Brobert, Panos Vardas, Stefan D. Anker, Diederick E. Grobbee, Spiros Denaxas, Diederick E. Grobbee, Folkert Asselbergs, Arno Hoes, Ghislaine van Thiel, Hans van Delden, René Eijkemans, Rolf Groenwold, Pieter Stolk, Olaf Klungel, Stefan D. Anker, Gerd P Hasenfuss, Stephan von Haehling, Panos Vardas, Aldo Maggioni, Gerhard Hindricks, Nikolaos Maniadakis, John Camm, Isabel Bardinet, Christina Dimopoulou, Susanne Løgstrup, Harry Hemingway, Richard Dobson, Aroon Hingorani, Spiros Denaxas, Folkert Asselbergs, JP Casas, Amitava Banerjee, Bernard de Bono, Tom Lumbers, Dan Swerdlow, Riyaz Patel, Claudia Langenberg, John Danesh, Adam Butterworth, Angela Wood, Jason Arora, Josep Redon, F.J. Chorro, Juan Carlos Pérez Cortés, J. Sanchis, J. Nuñez, V. Bodi, F. Martinez, Daniel Saez-Domingo, Jose L. Trillo, Lina Badimon, Tomas Jernberg, Henrik Olsson, Jonas Faxén, Tonje Thorvaldsen, Lars H Lund, Gianluigi Savarese, Stefan James, Bodil Svennblead, Stefan Blankenberg, Tanja Zeller, Renate Schnabel, Evert Ben van Veen, Paulus Kirchhof, Dipak Kotecha, Bodil Svennblead, Stefan James, Jonas Oldgren, Andrea Bayer, Gunnar Brobert, Tomasz Dyszynski, Christoph Gerlinger, Daniel Freitag, John Edward Butler-Ransohoff, Alex Asiimwe, Alexander Michel, Kiliana Suzart-Woischnik, Sebastian Kloss, Frederico Calado, Anders Gabrielsen, Vanessa Blanc, Nicolas Boisseau, Fabrice Couvelard, Willy Gosgnach, Olivier Gryson, Julien Hervouet, Weiwei Li-Bertheau, Benoît Tyl, Jessica Williams, Jessica Ash, Steve Williams, Rachel Ostroff, Alan Williams, Maureen Cronin, Vincent Fabian, Ong Siew Hwa, Avi Leaf, Kees van Bochove, Marinel Cavelaars, Maxim Moinat, Stefan Payralbe
Cohorts of millions of people's health records, whole genome sequencing, imaging, sensor, societal and publicly available data present a rapidly expanding digital trace of health. We aimed to critically review, for the first time, the challenges and potential of big data across early and late stages of translational cardiovascular disease research.
Renal denervation: will the Phoenix rise from the ashes? Eur. Heart J. (IF 19.651) Pub Date : 2017-08-29 Franz H. Messerli, Sripal Bangalore
On Monday, 28 August 28 2017 at 11 am, in the late breaking clinical trial session of the European Society of Cardiology (ESC) in Barcelona, the results of the SPYRAL HTN-OFF MED trial were reported and simultaneously published in the Lancet.1 Not surprisingly, the findings elicited a high level of interest because they stood in sharp contrast to those of SYMPLICITY HTN-3, a sham-controlled renal artery denervation (RDN) trial, which was sponsored by the same company (Medtronic) and published 3 years ago.2 As one may remember, this 535 patient blinded trial did not show a significant reduction of systolic blood pressure in patients with resistant hypertension 6 months after RDN as compared with a sham control.2 Irrational exuberance came to a grinding halt, ‘ugly facts...
Asian dust exposure triggers acute myocardial infarction Eur. Heart J. (IF 19.651) Pub Date : 2017-08-29 Sunao Kojima, Takehiro Michikawa, Kayo Ueda, Tetsuo Sakamoto, Kunihiko Matsui, Tomoko Kojima, Kenichi Tsujita, Hisao Ogawa, Hiroshi Nitta, Akinori Takami
To elucidate whether Asian dust is associated with the incidence of acute myocardial infarction (AMI) and to clarify whether patients who are highly sensitive to Asian dust will develop AMI.
Fibrosis as measured by the biomarker, tissue inhibitor metalloproteinase-1, predicts mortality in Age Gene Environment Susceptibility-Reykjavik (AGES-Reykjavik) Study Eur. Heart J. (IF 19.651) Pub Date : 2017-08-29 Gina LaRocca, Thor Aspelund, Anders M. Greve, Gudny Eiriksdottir, Tushar Acharya, Gudmundur Thorgeirsson, Tamara B. Harris, Lenore J. Launer, Vilmundur Gudnason, Andrew E. Arai
Fibrosis is a key pathological process in many chronic inflammatory disease states.
Improved outcomes in patients with ST-elevation myocardial infarction during the last 20 years are related to implementation of evidence-based treatments: experiences from the SWEDEHEART registry 1995–2014 Eur. Heart J. (IF 19.651) Pub Date : 2017-08-29 Karolina Szummer, Lars Wallentin, Lars Lindhagen, Joakim Alfredsson, David Erlinge, Claes Held, Stefan James, Thomas Kellerth, Bertil Lindahl, Annica Ravn-Fischer, Erik Rydberg, Troels Yndigegn, Tomas Jernberg
Impact of changes of treatments on outcomes in ST-elevation myocardial infarction (STEMI) patients in real-life health care has not been documented.
Effects of empagliflozin on risk for cardiovascular death and heart failure hospitalization across the spectrum of heart failure risk in the EMPA-REG OUTCOME® trial Eur. Heart J. (IF 19.651) Pub Date : 2017-08-28 David Fitchett, Javed Butler, Philippe van de Borne, Bernard Zinman, John M. Lachin, Christoph Wanner, Hans J. Woerle, Stefan Hantel, Jyothis T. George, Odd Erik Johansen, Silvio E. Inzucchi
Empagliflozin reduced the risk of cardiovascular (CV) death and heart failure (HF) hospitalizations in patients with type 2 diabetes (T2D) and established CV disease (CVD) in the EMPA-REG OUTCOME® trial. We investigated whether the benefit of empagliflozin was observed across the spectrum of HF risk.
Differential blood pressure effects of ibuprofen, naproxen, and celecoxib in patients with arthritis: the PRECISION-ABPM (Prospective Randomized Evaluation of Celecoxib Integrated Safety Versus Ibuprofen or Naproxen Ambulatory Blood Pressure Measurement) Trial Eur. Heart J. (IF 19.651) Pub Date : 2017-08-28 Frank Ruschitzka, Jeffrey S. Borer, Henry Krum, Andreas J. Flammer, Neville D. Yeomans, Peter Libby, Thomas F. Lüscher, Daniel H. Solomon, M. Elaine Husni, David Y. Graham, Deborah A. Davey, Lisa M. Wisniewski, Venu Menon, Rana Fayyad, Bruce Beckerman, Dinu Iorga, A. Michael Lincoff, Steven E. Nissen
Non-steroidal anti-inflammatory drugs (NSAIDs), both non-selective and selective cyclooxygenase-2 (COX-2) inhibitors, are among the most widely prescribed drugs worldwide, but associate with increased blood pressure (BP) and adverse cardiovascular (CV) events. PRECISION-ABPM, a substudy of PRECISION was conducted at 60 sites, to determine BP effects of the selective COX-2 inhibitor celecoxib vs. the non-selective NSAIDs naproxen and ibuprofen.
The role of cardiologists in stroke prevention and treatment: position paper of the European Society of Cardiology Council on Stroke Eur. Heart J. (IF 19.651) Pub Date : 2017-08-28 Petr Widimsky, Wolfram Doehner, Hans Christoph Diener, Isabelle C. Van Gelder, Alison Halliday, Mikael Mazighi
Stroke is a vascular disease with cerebral consequences, where the heart is a key player. It is defined as ‘a clinical syndrome typified by rapidly developing signs of focal or global disturbance of cerebral functions, lasting more than 24 h or leading to death, with no apparent causes other than of vascular origin’.1The incidence of stroke varies between 100–400 per 100 000 per year2 and mortality ranks second after coronary heart disease.3 Beyond mortality stroke is the largest single cause of physical disability in adults, second cause of dementia (after Alzheimer disease), major cause of depression, falls and epilepsy in the elderly. Stroke hence presents a tremendous burden both on patients as well as families and health care systems. Despite decreasing mortality rates in recent...
Report of an ESC-EAPCI Task Force on the evaluation and use of bioresorbable scaffolds for percutaneous coronary intervention: executive summary Eur. Heart J. (IF 19.651) Pub Date : 2017-08-28 Robert A. Byrne, Giulio G. Stefanini, Davide Capodanno, Yoshinobu Onuma, Andreas Baumbach, Javier Escaned, Michael Haude, Stefan James, Michael Joner, Peter Jüni, Adnan Kastrati, Semih Oktay, William Wijns, Patrick W. Serruys, Stephan Windecker
A previous Task Force of the European Society of Cardiology (ESC) and European Association of Percutaneous Cardiovascular Interventions (EAPCI) provided a report on recommendations for the non-clinical and clinical evaluation of coronary stents. Following dialogue with the European Commission, the Task Force was asked to prepare an additional report on the class of devices known as bioresorbable scaffolds (BRS). Five BRS have CE-mark approval for use in Europe. Only one device—the Absorb bioresorbable vascular scaffold—has published randomized clinical trial data and this data show inferior outcomes to conventional drug-eluting stents (DES) at 2–3 years. For this reason, at present BRS should not be preferred to conventional DES in clinical practice. The Task Force recommends that new BRS devices should undergo systematic non-clinical testing according to standardized criteria prior to evaluation in clinical studies. A clinical evaluation plan should include data from a medium sized, randomized trial against DES powered for a surrogate end point of clinical efficacy. Manufacturers of successful devices receive CE-mark approval for use and must have an approved plan for a large-scale randomized clinical trial with planned long-term follow-up.
Temporal trends in atrial fibrillation recurrence rates after ablation between 2005 and 2014: a nationwide Danish cohort study Eur. Heart J. (IF 19.651) Pub Date : 2017-08-28 Jannik Langtved Pallisgaard, Gunnar Hilmar Gislason, Jim Hansen, Arne Johannessen, Christian Torp-Pedersen, Peter Vibe Rasmussen, Morten Lock Hansen
During the last decade, ablation has increasingly been used in rhythm control management of patients with atrial fibrillation (AF). Over time, experience and techniques have improved and indications for ablation have expanded. The purpose of this study was to investigate whether the recurrence rate of AF following ablation has improved during last decade.
2017 ESC/EACTS Guidelines for the management of valvular heart disease: The Task Force for the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS) Eur. Heart J. (IF 19.651) Pub Date : 2017-08-26 Helmut Baumgartner, Volkmar Falk, Jeroen J. Bax, Michele De Bonis, Christian Hamm, Per Johan Holm, Bernard Iung, Patrizio Lancellotti, Emmanuel Lansac, Daniel Rodriguez Muñoz, Raphael Rosenhek, Johan Sjögren, Pilar Tornos Mas, Alec Vahanian, Thomas Walther, Olaf Wendler, Stephan Windecker, Jose Luis Zamorano, Marco Roffi, Ottavio Alfieri, Stefan Agewall, Anders Ahlsson, Emanuele Barbato, Héctor Bueno, Jean-Philippe Collet, Ioan Mircea Coman, Martin Czerny, Victoria Delgado, Donna Fitzsimons, Thierry Folliguet, Oliver Gaemperli, Gilbert Habib, Wolfgang Harringer, Michael Haude, Gerhard Hindricks, Hugo A. Katus, Juhani Knuuti, Philippe Kolh, Christophe Leclercq, Theresa A. McDonagh, Massimo Francesco Piepoli, Luc A. Pierard, Piotr Ponikowski, Giuseppe M. C. Rosano, Frank Ruschitzka, Evgeny Shlyakhto, Iain A. Simpson, Miguel Sousa-Uva, Janina Stepinska, Giuseppe Tarantini, Didier Tchétché, Victor Aboyans
The disclosure forms of all experts involved in the development of these guidelines are available on the ESC website http://www.escardio.org/guidelines.
2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) Eur. Heart J. (IF 19.651) Pub Date : 2017-08-26 Marco Valgimigli, Héctor Bueno, Robert A. Byrne, Jean-Philippe Collet, Francesco Costa, Anders Jeppsson, Peter Jüni, Adnan Kastrati, Philippe Kolh, Laura Mauri, Gilles Montalescot, Franz-Josef Neumann, Mate Petricevic, Marco Roffi, Philippe Gabriel Steg, Stephan Windecker, Jose Luis Zamorano, Glenn N. Levine, Lina Badimon, Pascal Vranckx, Stefan Agewall, Felicita Andreotti, Elliott Antman, Emanuele Barbato, Jean-Pierre Bassand, Raffaele Bugiardini, Mustafa Cikirikcioglu, Thomas Cuisset, Michele De Bonis, Victora Delgado, Donna Fitzsimons, Oliver Gaemperli, Nazzareno Galiè, Martine Gilard, Christian W. Hamm, Borja Ibanez, Bernard Iung, Stefan James, Juhani Knuuti, Ulf Landmesser, Christophe Leclercq, Maddalena Lettino, Gregory Lip, Massimo Francesco Piepoli, Luc Pierard, Markus Schwerzmann, Udo Sechtem, Iain A. Simpson, Miguel Sousa Uva, Eugenio Stabile, Robert F. Storey, Michal Tendera, Frans Van de Werf, Freek Verheugt, Victor Aboyans
The disclosure forms of all experts involved in the development of this focused update are available on the ESC website http://www.escardio.org/guidelines.
Questions and answers on diagnosis and management of patients with Peripheral Arterial Diseases: a companion document of the 2017 ESC Guidelines for the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS): Endorsed by: the European Stroke Organisation (ESO) The Task Force for the Diagnosis and Treatment of Peripheral Arterial Diseases of the European Society of Cardiology (ESC) and of the European Society for Vascular Surgery (ESVS) Eur. Heart J. (IF 19.651) Pub Date : 2017-08-26 Victor Aboyans, Martin Björck, Marianne Brodmann, Jean-Philippe Collet, Martin Czerny, Marco De Carlo, A. Ross Naylor, Marco Roffi, Michal Tendera, Charalambos Vlachopoulos, Jean-Baptiste Ricco, Petr Widimsky, Philippe Kolh, Florian Dick, Melina Vega de Ceniga, Massimo Francesco Piepoli, Horst Sievert, Jakub Sulzenko, Stephan Windecker, Victor Aboyans, Stefan Agewall, Emanuele Barbato, Héctor Bueno, Antonio Coca, Jean-Philippe Collet, Ioan Mircea Coman, Veronica Dean, Victoria Delgado, Donna Fitzsimons, Oliver Gaemperli, Gerhard Hindricks, Bernard Iung, Peter Jüni, Hugo A. Katus, Juhani Knuuti, Patrizio Lancellotti, Christophe Leclercq, Theresa McDonagh, Massimo Francesco Piepoli, Piotr Ponikowski, Dimitrios J. Richter, Marco Roffi, Evgeny Shlyakhto, Iain A. Simpson, Jose Luis Zamorano
A 76-year-old male is referred 48 hours after a transient ischaemic attack in the territory of the left carotid artery. He presented a recurrent episode of transient aphasia two hours prior to admission. He is not currently taking any medication. The duplex ultrasound scan (DUS) reveals a 60% stenosis of the left internal carotid artery (ICA) and non-stenotic plaques in the right ICA.
Clinical outcomes of state-of-the-art percutaneous coronary revascularization in patients with de novo three vessel disease: 1-year results of the SYNTAX II study Eur. Heart J. (IF 19.651) Pub Date : 2017-08-26 Javier Escaned, Carlos Collet, Nicola Ryan, Giovanni Luigi De Maria, Simon Walsh, Manel Sabate, Justin Davies, Maciej Lesiak, Raul Moreno, Ignacio Cruz-Gonzalez, Stephan P. Hoole, Nick Ej West, J. J. Piek, Azfar Zaman, Farzin Fath-Ordoubadi, Rodney H. Stables, Clare Appleby, Nicolas van Mieghem, Robert Jm. van Geuns, Neal Uren, Javier Zueco, Pawel Buszman, Andres Iñiguez, Javier Goicolea, David Hildick-Smith, Andrzej Ochala, Dariusz Dudek, Colm Hanratty, Rafael Cavalcante, Arie Pieter Kappetein, David P. Taggart, Gerrit-Anne van Es, Marie-Angèle Morel, Ton de Vries, Yoshinobu Onuma, Vasim Farooq, Patrick W. Serruys, Adrian P. Banning
To investigate if recent technical and procedural developments in percutaneous coronary intervention (PCI) significantly influence outcomes in appropriately selected patients with three-vessel (3VD) coronary artery disease.
Low-density lipoprotein: the culprit. From evidence to counselling, drugs, and vaccination Eur. Heart J. (IF 19.651) Pub Date : 2017-08-21 Thomas F. Lüscher
The Virtuous Circle Eur. Heart J. (IF 19.651) Pub Date : 2017-08-21 Alec Vahanian
A new vision from the ESC to connect knowledge, education, and registries, to improve the care of cardiology patients is discussed by Alec Vahanian
ACCA Masterclass Eur. Heart J. (IF 19.651) Pub Date : 2017-08-21 David Walker
The Acute Cardiovascular Care Association (ACCA) gathered professionals, experts and key opinion leaders to lead the way to the future in Acute Cardiovascular Care
Journal Metrics I Eur. Heart J. (IF 19.651) Pub Date : 2017-08-21 David Crotty
David Crotty PhD introduces metrics: the different methods for measuring and ranking journals
The Impact Factor Eur. Heart J. (IF 19.651) Pub Date : 2017-08-21 David Crotty
David Crotty PhD continues the discussion of Journal Metrics with the Impact Factor, a journal-level metric
Transvenous lead extraction Eur. Heart J. (IF 19.651) Pub Date : 2017-08-21 A Tofield
Cardiac lead extractions are safer in high-volume centres. Extraction in a low volume centre was associated with a doubled risk of death
Cecilia Linde MD Eur. Heart J. (IF 19.651) Pub Date : 2017-08-21
A new International Editorial Board member of the European Heart Journal
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel Eur. Heart J. (IF 19.651) Pub Date : 2017-04-24 Brian A. Ference, Henry N. Ginsberg, Ian Graham, Kausik K. Ray, Chris J. Packard, Eric Bruckert, Robert A. Hegele, Ronald M. Krauss, Frederick J. Raal, Heribert Schunkert, Gerald F. Watts, Jan Borén, Sergio Fazio, Jay D. Horton, Luis Masana, Stephen J. Nicholls, Børge G. Nordestgaard, Bart van de Sluis, Marja-Riitta Taskinen, Lale Tokgözoğlu, Ulf Landmesser, Ulrich Laufs, Olov Wiklund, Jane K. Stock, M. John Chapman, Alberico L. Catapano
To appraise the clinical and genetic evidence that low-density lipoproteins (LDLs) cause atherosclerotic cardiovascular disease (ASCVD).
Comprehensive efforts to increase adherence to statin therapy Eur. Heart J. (IF 19.651) Pub Date : 2017-01-10 Alexander Vonbank, Stefan Agewall, Keld Per Kjeldsen, Basil S. Lewis, Christian Torp-Pedersen, Claudio Ceconi, Christian Funck-Brentano, Juan Carlos Kaski, Alexander Niessner, Juan Tamargo, Thomas Walther, Sven Wassmann, Giuseppe Rosano, Harald Schmidt, Christoph H. Saely, Heinz Drexel
Previous work from the European Society of Cardiology (ESC), the European Atherosclerosis Society (EAS) and from other groups has addressed the benefits of statin treatment in different patient populations.1–4 Unfortunately, adherence to guideline-recommended statin therapy is suboptimal: Statins are underused and LDL cholesterol targets are not met in up to 80% of high-risk patients.5–7
Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies Eur. Heart J. (IF 19.651) Pub Date : 2017-04-12 Christian M. Madsen, Anette Varbo, Børge G. Nordestgaard
High-density lipoprotein (HDL) cholesterol concentrations are inversely associated with cardiovascular disease and mortality across a range of concentrations, but genetic evidence suggest that extreme high concentrations may paradoxically lead to more cardiovascular disease. We tested the hypothesis that extreme high concentrations of HDL cholesterol are associated with high all-cause mortality in men and women.
HDL cholesterol concentration or HDL function: which matters? Eur. Heart J. (IF 19.651) Pub Date : 2017-05-19 Philip J. Barter, Kerry-Anne Rye
This editorial refers to ‘Extreme high high-density lipoprotein cholesterol is paradoxically associated with high mortality in men and women: two prospective cohort studies’†, by C.M. Madsen et al., on page 2478.
Lipoprotein(a) and the risk of cardiovascular disease in the European population: results from the BiomarCaRE consortium Eur. Heart J. (IF 19.651) Pub Date : 2017-04-24 Christoph Waldeyer, Nataliya Makarova, Tanja Zeller, Renate B. Schnabel, Fabian J. Brunner, Torben Jørgensen, Allan Linneberg, Teemu Niiranen, Veikko Salomaa, Pekka Jousilahti, John Yarnell, Marco M. Ferrario, Giovanni Veronesi, Paolo Brambilla, Stefano G. Signorini, Licia Iacoviello, Simona Costanzo, Simona Giampaoli, Luigi Palmieri, Christa Meisinger, Barbara Thorand, Frank Kee, Wolfgang Koenig, Francisco Ojeda, Jukka Kontto, Ulf Landmesser, Kari Kuulasmaa, Stefan Blankenberg
As promising compounds to lower Lipoprotein(a) (Lp(a)) are emerging, the need for a precise characterization and comparability of the Lp(a)-associated cardiovascular risk is increasing. Therefore, we aimed to evaluate the distribution of Lp(a) concentrations across the European population, to characterize the association with cardiovascular outcomes and to provide high comparability of the Lp(a)-associated cardiovascular risk by use of centrally determined Lp(a) concentrations.
The AT04A vaccine against proprotein convertase subtilisin/kexin type 9 reduces total cholesterol, vascular inflammation, and atherosclerosis in APOE*3Leiden.CETP mice Eur. Heart J. (IF 19.651) Pub Date : 2017-06-19 Christine Landlinger, Marianne G. Pouwer, Claudia Juno, José W.A. van der Hoorn, Elsbet J. Pieterman, J. Wouter Jukema, Guenther Staffler, Hans M.G. Princen, Gergana Galabova
Proprotein convertase subtilisin/kexin type 9 (PCSK9) has emerged as a promising therapeutic target for the treatment of hypercholesterolaemia and atherosclerosis. PCSK9 binds to the low density lipoprotein receptor and enhances its degradation, which leads to the reduced clearance of low density lipoprotein cholesterol (LDLc) and a higher risk of atherosclerosis. In this study, the AT04A anti-PCSK9 vaccine was evaluated for its therapeutic potential in ameliorating or even preventing coronary heart disease in the atherogenic APOE*3Leiden.CETP mouse model.
Some contents have been Reproduced by permission of The Royal Society of Chemistry.
- Acad. Manag. Ann.
- Acc. Chem. Res.
- ACS Appl. Mater. Interfaces
- ACS Biomater. Sci. Eng.
- ACS Catal.
- ACS Cent. Sci.
- ACS Chem. Biol.
- ACS Chem. Neurosci.
- ACS Comb. Sci.
- ACS Earth Space Chem.
- ACS Energy Lett.
- ACS Infect. Dis.
- ACS Macro Lett.
- ACS Med. Chem. Lett.
- ACS Nano
- ACS Omega
- ACS Photonics
- ACS Sens.
- ACS Sustainable Chem. Eng.
- ACS Synth. Biol.
- Acta Mater.
- Acta Neuropathol.
- Adv. Drug Deliver. Rev.
- Adv. Electron. Mater.
- Adv. Energy Mater.
- Adv. Funct. Mater.
- Adv. Healthcare Mater.
- Adv. Mater.
- Adv. Opt. Photon.
- Adv. Phys.
- Adv. Sci.
- Adv. Synth. Catal.
- AlChE J.
- Am. J. Psychiatry
- Am. J. Respir. Crit. Care Med.
- Anal. Chem.
- Anal. Chim. Acta
- Anal. Methods
- Angew. Chem. Int. Ed.
- Ann. Intern. Med.
- Ann. Oncol.
- Ann. Rheum. Dis.
- Annu. Rev. Anal. Chem.
- Annu. Rev. Astron. Astrophys.
- Annu. Rev. Biochem.
- Annu. Rev. Biomed. Eng.
- Annu. Rev. Biophys.
- Annu. Rev. Cell Dev. Biol.
- Annu. Rev. Clin. Psychol.
- Annu. Rev. Condens. Matter Phys.
- Annu. Rev. Ecol. Evol. Syst.
- Annu. Rev. Entomol.
- Annu. Rev. Fluid Mech.
- Annu. Rev. Immunol.
- Annu. Rev. Mar. Sci.
- Annu. Rev. Mater. Res.
- Annu. Rev. Med.
- Annu. Rev. Microbiol.
- Annu. Rev. Neurosci.
- Annu. Rev. Pathol. Mech. Dis.
- Annu. Rev. Pharmacol. Toxicol.
- Annu. Rev. Phys. Chem.
- Annu. Rev. Physiol.
- Annu. Rev. Phytopathol.
- Annu. Rev. Plant Biol.
- Annu. Rev. Psychol.
- Annu. Rev. Publ. Health
- Annu. Rev. Virol.
- Antivir. Res.
- Appl. Catal. A Gen.
- Appl. Catal. B Environ.
- Appl. Energy
- Appl. Phys. Lett.
- Appl. Phys. Rev.
- Asian J. Org. Chem.
- CA: Cancer J. Clin.
- Cancer Cell
- Cancer Discov.
- Carbohydr. Polym.
- Catal. Sci. Technol.
- Catal. Today
- Cell Chem. Bio.
- Cell Host Microbe
- Cell Metab.
- Cell Res.
- Cell Stem Cell
- Ceram. Int.
- Chem. Asian J.
- Chem. Commun.
- Chem. Educ. Res. Pract.
- Chem. Eng. J.
- Chem. Eur. J.
- Chem. Mater.
- Chem. Phys.
- Chem. Phys. Lett.
- Chem. Res. Toxicol.
- Chem. Rev.
- Chem. Sci.
- Chem. Soc. Rev.
- Circ. Res.
- Clin. Microbiol. Rev.
- Compos. Part A Appl. Sci. Manuf.
- Comput. Fluids
- Coordin. Chem. Rev.
- Corros. Sci.
- Crit. Rev. Food Sci. Nutr.
- Cryst. Growth Des.
- Electrochem. Commun.
- Electrochim. Acta
- Endocr. Rev.
- Energy Environ. Sci.
- Energy Fuels
- Environ. Pollut.
- Environ. Sci. Technol.
- Environ. Sci. Technol. Lett.
- Environ. Sci.: Nano
- Environ. Sci.: Processes Impacts
- Environ. Sci.: Water Res. Technol.
- Eur. Heart J.
- Eur. J. Inorg. Chem.
- Eur. J. Med. Chem.
- Eur. J. Org. Chem.
- Eur. Polym. J.
- Eur. Respir. J.
- Eur. Urol.
- Electrochem. Commun.
- Electrochim. Acta
- Endocr. Rev.
- Energy Environ. Sci.
- Energy Fuels
- Environ. Pollut.
- Environ. Sci. Technol.
- Environ. Sci. Technol. Lett.
- Environ. Sci.: Nano
- Environ. Sci.: Processes Impacts
- Environ. Sci.: Water Res. Technol.
- Eur. Heart J.
- Eur. J. Inorg. Chem.
- Eur. J. Med. Chem.
- Eur. J. Org. Chem.
- Eur. Polym. J.
- Eur. Respir. J.
- Eur. Urol.
- J Nucl. Med.
- J. Agric. Food Chem.
- J. Allergy Clin. Immunol.
- J. Alloys Compd.
- J. Am. Ceram. Soc.
- J. Am. Chem. Soc.
- J. Am. Coll. Cardiol.
- J. Anal. At. Spectrom.
- J. Antibiot.
- J. Catal.
- J. Chem. Educ.
- J. Chem. Eng. Data
- J. Chem. Inf. Model.
- J. Chem. Phys.
- J. Chem. Theory Comput.
- J. Chromatogr. A
- J. Chromatogr. B
- J. Clin. Invest.
- J. Clin. Oncol.
- J. Comput. Chem.
- J. Comput. Phys.
- J. Control. Release
- J. Cryst. Growth
- J. Electrochem. Soc.
- J. Eur. Ceram. Soc.
- J. Exp. Med.
- J. Fluid Mech.
- J. Funct. Foods
- J. Hazard. Mater.
- J. Hepatol.
- J. Mater. Chem. A
- J. Mater. Chem. B
- J. Mater. Chem. C
- J. Med. Chem.
- J. Membr. Sci.
- J. Nat. Gas Sci. Eng.
- J. Nat. Prod.
- J. Natl. Cancer Inst.
- J. Org. Chem.
- J. Photochem. Photobiol. C Photochem. Rev.
- J. Phys. Chem. A
- J. Phys. Chem. B
- J. Phys. Chem. C
- J. Phys. Chem. Lett.
- J. Pineal. Res.
- J. Power Sources
- J. Proteome Res.
- J. Virol.
- JACC Cardiovasc. Imag.
- JAMA Intern. Med.
- JAMA Oncol.
- JAMA Pediatr.
- JAMA Psychiatry
- Macromol. Rapid Commun.
- Mater. Chem. Front.
- Mater. Des.
- Mater. Horiz.
- Mater. Sci. Eng. A
- Mater. Sci. Eng. R Rep.
- Mater. Today
- Meat Sci.
- Med. Chem. Commun.
- Med. Res. Rev.
- Microbiol. Mol. Biol. Rev.
- Microchim. Acta
- Mol. Biosyst.
- Mol. Cancer Ther.
- Mol. Catal.
- Mol. Cell
- Mol. Pharmaceutics
- Mol. Psychiatry
- Mol. Syst. Des. Eng.
- N. Engl. J. Med.
- Nano Energy
- Nano Lett.
- Nano Res.
- Nano Today
- Nano-Micro Lett.
- Nanoscale Horiz.
- Nat. Biomed. Eng.
- Nat. Biotechnol.
- Nat. Cell. Biol.
- Nat. Chem.
- Nat. Chem. Biol.
- Nat. Clim. Change
- Nat. Commun.
- Nat. Energy
- Nat. Genet.
- Nat. Geosci.
- Nat. Immunol.
- Nat. Mater.
- Nat. Med.
- Nat. Methods
- Nat. Microbiol.
- Nat. Nanotech.
- Nat. Neurosci.
- Nat. Photon.
- Nat. Phys.
- Nat. Plants
- Nat. Prod. Rep.
- Nat. Protoc.
- Nat. Rev. Cancer
- Nat. Rev. Cardiol.
- Nat. Rev. Chem.
- Nat. Rev. Clin. Oncol.
- Nat. Rev. Drug. Disc.
- Nat. Rev. Endocrinol.
- Nat. Rev. Gastroenterol. Hepatol.
- Nat. Rev. Genet.
- Nat. Rev. Immunol.
- Nat. Rev. Mater.
- Nat. Rev. Microbiol.
- Nat. Rev. Mol. Cell Biol.
- Nat. Rev. Nephrol.
- Nat. Rev. Neurol.
- Nat. Rev. Neurosci.
- Nat. Rev. Rheumatol.
- Nat. Struct. Mol. Biol.
- New J. Chem.
- NPG Asia Mater.
- Nucleic Acids Res.